Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Suzanne M. Grieb, Robert Harris, Amanda Rosecrans, Katie Zook, Susan G. Sherman, Adena Greenbaum, Gregory M. Lucas & Kathleen R. Page. (2022) Awareness, perception and utilization of a mobile health clinic by people who use drugs. Annals of Medicine 54:1, pages 138-149.
Read now
Read now
Shashi N. Kapadia, Judith L. Griffin, Justine Waldman, Nicolas R. Ziebarth, Bruce R. Schackman & Czarina N. Behrends. (2022) The Experience of Implementing a Low-Threshold Buprenorphine Treatment Program in a Non-Urban Medical Practice. Substance Use & Misuse 57:2, pages 308-315.
Read now
Read now
Jermaine D. Jones, Aimee N. Campbell, Laura Brandt, Felipe Castillo, Rebecca Abbott & Sandra D. Comer. (2021) Intervention in an opioid overdose event increases interest in treatment among individuals with opioid use disorder. Substance Abuse 42:4, pages 407-411.
Read now
Read now
Benjamin T. Hayes, Andrea Jakubowski, Christine Fitzsimmons, Billy Garcia, Franklin Ramirez & Aaron D. Fox. (2021) “The Doctor Says You Cannot Have [Buprenorphine]” Autonomy and Use of Prescribed or Non-Prescribed Buprenorphine. Substance Use & Misuse 56:8, pages 1137-1143.
Read now
Read now
Julia E. Hood, Caleb J. Banta-Green, Jeffrey S. Duchin, Joseph Breuner, Wendy Dell, Brad Finegood, Sara N. Glick, Malin Hamblin, Shayla Holcomb, Darla Mosse, Thea Oliphant-Wells & Mi-Hyun Mia Shim. (2020) Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: Lessons learned from Seattle, Washington. Substance Abuse 41:3, pages 356-364.
Read now
Read now
Marcus A. Bachhuber$suffix/text()$suffix/text(), Cole Thompson$suffix/text()$suffix/text(), Ann Prybylowski$suffix/text()$suffix/text(), José Benitez$suffix/text()$suffix/text(), Silvana Mazzella$suffix/text()$suffix/text() & David Barclay$suffix/text()$suffix/text(). (2018) Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program. Substance Abuse 39:2, pages 167-172.
Read now
Read now
Traci Rieckmann, John Muench, Mary Ann McBurnie, Michael C. Leo, Phillip Crawford, Daren Ford, Jennifer Stubbs, Conall O’Cleirigh, Kenneth H. Mayer, Kevin Fiscella, Nicole Wright, Maya Doe-Simkins, Matthew Cuddeback, Elizabeth Salisbury-Afshar & Christine Nelson. (2016) Medication-assisted treatment for substance use disorders within a national community health center research network. Substance Abuse 37:4, pages 625-634.
Read now
Read now
Sharon Stancliff, Benjamin W. Phillips, Nazlee Maghsoudi & Herman Joseph. (2015) Harm Reduction: Front Line Public Health. Journal of Addictive Diseases 34:2-3, pages 206-219.
Read now
Read now
Aaron D. Fox, Adam Chamberlain, Taeko Frost & Chinazo O. Cunningham. (2015) Harm Reduction Agencies as a Potential Site for Buprenorphine Treatment. Substance Abuse 36:2, pages 155-160.
Read now
Read now
R. Terry Furst & Douglas N. Evans. (2015) An Exploration of Stigma in the Lives of Sex Offenders and Heroin Abusers. Deviant Behavior 36:2, pages 130-145.
Read now
Read now
AaronD. Fox, PoojaA. Shah, NancyL. Sohler, CarolinaM. Lopez, JoannaL. Starrels & ChinazoO. Cunningham. (2014) I Heard About It from a Friend: Assessing Interest in Buprenorphine Treatment. Substance Abuse 35:1, pages 74-79.
Read now
Read now
Articles from other publishers (43)
Sarah E. Messmer, Abigail T. Elmes, Antonio D. Jimenez, Albert Leon Murphy, Miriam Guzman, Dennis P. Watson, Elisabeth Poorman, Stockton Mayer, Alexander F. Infante, Eden G. Keller, Kevin Whitfield & Jennie B. Jarrett. (2023) Outcomes of a mobile medical unit for low-threshold buprenorphine access targeting opioid overdose hot spots in Chicago. Journal of Substance Use and Addiction Treatment 150, pages 209054.
Crossref
Crossref
Andrea Jakubowski, Sabrina Fowler & Aaron D. Fox. (2023) Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature. Addiction Science & Clinical Practice 18:1.
Crossref
Crossref
Amy Corneli, Brian Perry, Andrea Des Marais, Yujung Choi, Hillary Chen, Rebecca Lilly, Denae Ayers, Jesse Bennett, Lauren Kestner, Christina S. Meade, Nidhi Sachdeva & Mehri S. McKellar. (2022) Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation. Harm Reduction Journal 19:1.
Crossref
Crossref
Andrea Jakubowski, Caroline Rath, Alex Harocopos, Monique Wright, Alice Welch, Jessica Kattan, Czarina Navos Behrends, Teresa Lopez-Castro & Aaron D. Fox. (2022) Implementation of buprenorphine services in NYC syringe services programs: a qualitative process evaluation. Harm Reduction Journal 19:1.
Crossref
Crossref
Jamie Carter, Zhen Li, Hillary Chen, Melissa Greiner, Christopher Bush, Debanjan Bhattacharya, Stephanie Poley, Nidhi Sachdeva, Jane Carolyn Crowder & Jacob Feigal. (2022) Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study. Addiction Science & Clinical Practice 17:1.
Crossref
Crossref
Joëlla W. Adams, Alexandra Savinkina, Aaron Fox, Czarina N. Behrends, Rajapaksha W. M. A. Madushani, Jianing Wang, Avik Chatterjee, Alexander Y. Walley, Joshua A. Barocas & Benjamin P. Linas. (2022) Modeling the cost‐effectiveness and impact on fatal overdose and initiation of buprenorphine–naloxone treatment at syringe service programs. Addiction 117:10, pages 2635-2648.
Crossref
Crossref
Noa Krawczyk, Sean T. Allen, Kristin E. Schneider, Keisha Solomon, Hridika Shah, Miles Morris, Samantha J. Harris, Susan G. Sherman & Brendan Saloner. (2022) Intersecting substance use treatment and harm reduction services: exploring the characteristics and service needs of a community-based sample of people who use drugs. Harm Reduction Journal 19:1.
Crossref
Crossref
Julia Dickson-Gomez, Sarah Krechel, Dan Katende, Bryan Johnston, Wamala Twaibu, Laura Glasman, Moses Ogwal & Geofrey Musinguzi. (2022) The Role of Context in Integrating Buprenorphine into a Drop-In Center in Kampala, Uganda, Using the Consolidated Framework for Implementation Research. International Journal of Environmental Research and Public Health 19:16, pages 10382.
Crossref
Crossref
Andrea Jakubowski, Brianna L. Norton, Benjamin T. Hayes, Brent E. Gibson, Christine Fitzsimmons, L. Synn Stern, Franklin Ramirez, Mercedes Guzman, Susan Spratt, Pia Marcus & Aaron D. Fox. (2022) Low-threshold Buprenorphine Treatment in a Syringe Services Program: Program Description and Outcomes. Journal of Addiction Medicine 16:4, pages 447-453.
Crossref
Crossref
Shailina Keshwani, Michael Maguire, Amie Goodin, Wei-Hsuan Lo-Ciganic, Debbie L. Wilson & Juan M. Hincapie-Castillo. (2022) Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs. JAMA Health Forum 3:6, pages e221757.
Crossref
Crossref
Andres Perez-Correa, Bilal Abbas, Lindsey Riback, Megan Ghiroli, Brianna Norton, Sean Murphy, Andrea Jakubowski, Benjamin T. Hayes, Chinazo O. Cunningham & Aaron D. Fox. (2022) Onsite buprenorphine inductions at harm reduction agencies to increase treatment engagement and reduce HIV risk: Design and rationale. Contemporary Clinical Trials 114, pages 106674.
Crossref
Crossref
Andreas Pilarinos, Daniel J. Bromberg & Mohammad Karamouzian. (2022)
A
ccess to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults
. JAMA Pediatrics 176:3, pages 304.
Crossref
Crossref
Kristi Hill, Laura Nussdorf, Julia D. Mount, Rachel Silk, Chloe Gross, David Sternberg, Phyllis Bijole, Miriam Jones, Randy Kier, Dana Mccullough, Poonam Mathur, Shyam Kottilil, Henry Masur, Sarah Kattakuzhy & Elana S. Rosenthal. (2022) Initiation of Low-threshold Buprenorphine in Nontreatment Seeking Patients With Opioid Use Disorder Engaged in Hepatitis C Treatment. Journal of Addiction Medicine 16:1, pages 10-17.
Crossref
Crossref
Ellis Jaewon Yeo, Hannah Kralles, David Sternberg, Dana McCullough, Ajetha Nadanasabesan, Richard Mayo, Hana Akselrod & Jillian Catalanotti. (2021) Implementing a low-threshold audio-only telehealth model for medication-assisted treatment of opioid use disorder at a community-based non-profit organization in Washington, D.C.. Harm Reduction Journal 18:1.
Crossref
Crossref
Aurélie Tinland, Sandrine Loubiere, Matthieu Cantiello, Mohamed Boucekine, Vincent Girard, Owen Taylor & Pascal Auquier. (2021) Mortality in homeless people enrolled in the French housing first randomized controlled trial: a secondary outcome analysis of predictors and causes of death. BMC Public Health 21:1.
Crossref
Crossref
Amanda R. W. Berry, Tracy L. Finlayson, Luke M. Mellis & Lianne A. Urada. (2021) Association between Participation in Counseling and Retention in a Buprenorphine-Assisted Treatment Program for People Experiencing Homelessness with Opioid Use Disorder. International Journal of Environmental Research and Public Health 18:21, pages 11072.
Crossref
Crossref
Courtney D. Nordeck, Megan Buresh, Noa Krawczyk, Michael Fingerhood & Deborah Agus. (2021) Adapting a Low-threshold Buprenorphine Program for Vulnerable Populations During the COVID-19 Pandemic. Journal of Addiction Medicine 15:5, pages 364-369.
Crossref
Crossref
David T. O'Gurek, Jillian Jatres, Jonetta Gibbs, Ian Latham, Byron Udegbe & Kathleen Reeves. (2021) Expanding buprenorphine treatment to people experiencing homelessness through a mobile, multidisciplinary program in an urban, underserved setting. Journal of Substance Abuse Treatment 127, pages 108342.
Crossref
Crossref
Matthew F. McLaughlin, Rick Li, Nicolás Domínguez Carrero, Paul A. Bain & Avik Chatterjee. (2021) Opioid use disorder treatment for people experiencing homelessness: A scoping review. Drug and Alcohol Dependence 224, pages 108717.
Crossref
Crossref
Danielle R. Fine, Elizabeth Lewis, Karen Weinstock, Joseph Wright, Jessie M. Gaeta & Travis P. Baggett. (2021) Office-Based Addiction Treatment Retention and Mortality Among People Experiencing Homelessness. JAMA Network Open 4:3, pages e210477.
Crossref
Crossref
Vincent Wagner, Yan Ferguson, Karine Hudon, Marie-Ève Goyer & Jorge Flores-Aranda. (2021) Précarité et usage d’opioïdes : revue narrative sur l’approche à bas seuil d’exigencePrecarity and opioid use: a narrative review on the low threshold approachPrecariedad y consumo de opioides: revisión narrativa de un enfoque de bajo umbral de exigencia. Drogues, santé et société 19:1-2, pages 66.
Crossref
Crossref
Pablo K. Valente, Angela R. Bazzi, Ellen Childs, Peter Salhaney, Joel Earlywine, Jennifer Olson, Dea L. Biancarelli, Brandon D.L. Marshall & Katie B. Biello. (2020) Patterns, contexts, and motivations for polysubstance use among people who inject drugs in non-urban settings in the U.S. Northeast. International Journal of Drug Policy 85, pages 102934.
Crossref
Crossref
Payel Jhoom Roy, Sugy Choi, Edward Bernstein & Alexander Yale Walley. (2020) Appointment wait-times and arrival for patients at a low-barrier access addiction clinic. Journal of Substance Abuse Treatment 114, pages 108011.
Crossref
Crossref
Lara Carson WeinsteinQais IqbalAmy CunninghamRobin DebatesGreg LandistratisPatrick DoggettAlexis Silverio. (2020) Retention of Patients With Multiple Vulnerabilities in a Federally Qualified Health Center Buprenorphine Program: Pennsylvania, 2017–2018. American Journal of Public Health 110:4, pages 580-586.
Crossref
Crossref
Andrea Jakubowski & Aaron Fox. (2020) Defining Low-threshold Buprenorphine Treatment. Journal of Addiction Medicine 14:2, pages 95-98.
Crossref
Crossref
Michael Stein, Debra Herman, Micah Conti, Bradley Anderson & Genie Bailey. (2019) Initiating buprenorphine treatment for opioid use disorder during short‐term in‐patient ‘detoxification’: a randomized clinical trial. Addiction 115:1, pages 82-94.
Crossref
Crossref
Jamie Carter, Barry Zevin & Paula J. Lum. (2019) Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. Addiction Science & Clinical Practice 14:1.
Crossref
Crossref
Jennifer McNeely, Andrea B. Troxel, Hillary V. Kunins, Donna Shelley, Joshua D. Lee, Alexander Walley, Zoe M. Weinstein, John Billings, Nichola J. Davis, Roopa Kalyanaraman Marcello, Bruce R. Schackman, Charles Barron & Luke Bergmann. (2019) Study protocol for a pragmatic trial of the Consult for Addiction Treatment and Care in Hospitals (CATCH) model for engaging patients in opioid use disorder treatment. Addiction Science & Clinical Practice 14:1.
Crossref
Crossref
Evan S. Schwarz, JoAn R. Laes & Timothy J. Wiegand. (2019) A New Way Forward in the Emergency Department. Journal of Medical Toxicology 15:4, pages 220-222.
Crossref
Crossref
Blair Bishop, Jean Gilmour & Daryle Deering. (2019) Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder. International Journal of Mental Health Nursing 28:1, pages 226-236.
Crossref
Crossref
Aaron D. Fox, Andrea U. Jakubowski & Jonathan Giftos. 2019. Treating Opioid Addiction. Treating Opioid Addiction
197
222
.
Elenore Patterson Bhatraju, Ellie Grossman, Babak Tofighi, Jennifer McNeely, Danae DiRocco, Mara Flannery, Ann Garment, Keith Goldfeld, Marc N. Gourevitch & Joshua D. Lee. (2017) Public sector low threshold office-based buprenorphine treatment: outcomes at year 7. Addiction Science & Clinical Practice 12:1.
Crossref
Crossref
Aaron D. Fox, Nancy L. Sohler, Taeko Frost, Carolina Lopez & Chinazo O. Cunningham. (2017) Development and evaluation of a community-based buprenorphine treatment intervention. Harm Reduction Journal 14:1.
Crossref
Crossref
Jermaine D. Jones, Aimee Campbell, Verena E. Metz & Sandra D. Comer. (2017) No evidence of compensatory drug use risk behavior among heroin users after receiving take-home naloxone. Addictive Behaviors 71, pages 104-106.
Crossref
Crossref
SAMEER HASSAMAL, MATTHEW GOLDENBERG, WAGUIH ISHAK, MARGARET HAGLUND, KAREN MIOTTO & ITAI DANOVITCH. (2017) Overcoming Barriers to Initiating Medication-assisted Treatment for Heroin Use Disorder in a General Medical Hospital: A Case Report and Narrative Literature Review. Journal of Psychiatric Practice 23:3, pages 221-229.
Crossref
Crossref
Elliott J. Liebling, Jesse L. Yedinak, Traci C. Green, Scott E. Hadland, Melissa A. Clark & Brandon D. L. Marshall. (2016) Access to substance use treatment among young adults who use prescription opioids non-medically. Substance Abuse Treatment, Prevention, and Policy 11:1.
Crossref
Crossref
Helena Hansen, Carole Siegel, Joseph Wanderling & Danae DiRocco. (2016) Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. Drug and Alcohol Dependence 164, pages 14-21.
Crossref
Crossref
Jermaine D. Jones, Jared J. Atchison, Gabriela Madera, Verena E. Metz & Sandra D. Comer. (2015) Need and utility of a polyethylene glycol marker to ensure against urine falsification among heroin users. Drug and Alcohol Dependence 153, pages 201-206.
Crossref
Crossref
Rolando Tringale, Andrew M. Subica, Arman Danielian & Charles Kaplan. (2015) The Stepped Treatment Engagement Protocol for Homeless, Needle Exchange Heroin-Dependent Patients. Journal of Addiction Medicine 9:2, pages 163-164.
Crossref
Crossref
Aaron D. Fox, Adam Chamberlain, Nancy L. Sohler, Taeko Frost & Chinazo O. Cunningham. (2015) Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants. Journal of Substance Abuse Treatment 48:1, pages 112-116.
Crossref
Crossref
Lyn Stankiewicz Murphy, Marla T. Oros & Susan G. Dorsey. (2014) The Baltimore Buprenorphine Initiative. Journal of Addictions Nursing 25:1, pages 16-25.
Crossref
Crossref
Thomas A. Nguyen, Jennie H. Hahn & Stephen M. Strakowski. (2013) Pharmacotherapies for treating opioid use disorder. CNS Spectrums 18:6, pages 289-295.
Crossref
Crossref
Richard J. Bodnar. (2013) Endogenous opiates and behavior: 2012. Peptides 50, pages 55-95.
Crossref
Crossref